NCT04914767 (Nigelle5) is a Phase 1 clinical trial of Nigella in SARS-CoV2 Infection, sponsored by Hôpital Universitaire Sahloul.

Who is sponsoring NCT04914767?

NCT04914767 is sponsored by Hôpital Universitaire Sahloul.

What drugs are being tested in NCT04914767?

Interventions in NCT04914767: Nigella, Placebo.

What condition does NCT04914767 study?

NCT04914767 studies SARS-CoV2 Infection.

Is NCT04914767 still recruiting?

NCT04914767 is currently completed. Last updated 21 February 2022.

Last reviewed 2022-02-21 · How we verify

NCT04914767: Nigelle5

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nigella 5 in the Treatment of SARS COV2 (COVID-19)

Completed Phase 1 Last updated 21 February 2022

What this trial tests

Phase 1 trial testing Nigella in SARS-CoV2 Infection in 500 participants. Completed in 31 December 2021.

Timeline

1 March 2021

Primary endpoint
30 October 2021

31 December 2021

Quick facts

Lead sponsor	Hôpital Universitaire Sahloul
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	500
Start date	1 March 2021
Primary completion	30 October 2021
Estimated completion	31 December 2021
Sites	2 locations across Tunisia

Drugs / interventions tested

Nigella — full drug profile →
Placebo

Conditions studied

SARS-CoV2 Infection — all drugs for SARS-CoV2 Infection →

Sponsor

Hôpital Universitaire Sahloul — full company profile →

Who can join

40 and older, any sex, with SARS-CoV2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The world is currently facing a crisis because of this potentially fatal situation of the COVID-19 epidemic without proven efficacy for any drug treatment, while the vaccination is not yet. This epidemic is caused by a new betacorona virus, now called SARS-CoV-2. The most common symptoms reported are fever, cough or chest tightness, and dyspnea. Most cases have a mild course

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

<i>Nigella sativa</i>: A Comprehensive Review of Its Therapeutic Potential, Pharmacological Properties, and Clinical Applications.
Alberts A, Moldoveanu ET, Niculescu AG, Grumezescu AM. · · 2024 · cited 12× · PMID 39769174 · DOI 10.3390/ijms252413410
<i>Nigella sativa</i> L. and COVID-19: A Glance at The Anti-COVID-19 Chemical Constituents, Clinical Trials, Inventions, and Patent Literature.
Imran M, Khan SA, Abida, Alshammari MK, et al · · 2022 · cited 10× · PMID 35566101 · DOI 10.3390/molecules27092750

Verify or expand the search:

Other trials of Nigella

Trials testing the same drug.

NCT04989101 — Nigelle 5 in Prevention of Influanza · NA · completed

Other recruiting trials for SARS-CoV2 Infection

Currently open trials in the same condition.

NCT05852873 — PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway · Phase 3 · active not recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04830852 — Pediatric COVID Outcomes Study (PECOS) · active not recruiting
NCT04844242 — MISC COVID-19 Study in Pediatric Population · recruiting

Other Hôpital Universitaire Sahloul trials

Trials by the same sponsor.

NCT07329881 — Artificial Intelligence Algorithm for the Interpretation of Traumatic Bone Radiographs · active not recruiting
NCT07147699 — Evaluation of the Effectiveness of the CardioStory Device in Distinguishing Heart Failure From Other Causes in Patients · not yet recruiting
NCT07089277 — External Validation of the Glasgow-Blatchford Bleeding Score in a Tunisian Population · recruiting
NCT06953154 — Monocyte Distribution Width (MDW): An Early Marker of Sepsis in Patients With Comorbidities · completed
NCT05646433 — Validation of a New Score for UGI Bleeding in the ED: the Study of the TU-GIB Score · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04914767 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hôpital Universitaire Sahloul
Last refreshed: 21 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04914767.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing